IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.

ABSTRACT: Background Enhanced inflammation may lead to exercise intolerance in heart failure with preserved ejection fraction. The aim of the current study was to determine whether IL (interleukin)-1 blockade with anakinra improved cardiorespiratory fitness in heart failure with preserved ejection fraction. Methods and Results Thirty-one patients with heart failure with preserved ejection fraction and CRP (C-reactive protein) >2 mg/L were randomized to anakinra (100 mg subcutaneously daily, N=21) or placebo (N=10) for 12 weeks. We measured peak oxygen consumption (Vo₂), ventilatory efficiency (V_E/Vco₂ slope), and high-sensitivity CRP and NT-proBNP (N-terminal pro-B-type natriuretic peptide) at 4, 12, and 24 weeks. Twenty-eight patients completed ≥2 visits, 18 women (

SUBMITTER: Van Tassell BW 

PROVIDER: S-EPMC6545106 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature